Graves' Ophthalmopathy Market Poised for 9% Annual Growth Through 2036

Global market size for these treatments reached USD 3.5 billion in 2025, with the United States representing the largest share of the 2.4 million prevalent cases identified across the seven major markets. While Amgen’s TEPEZZA currently holds a dominant position as the only disease-specific therapy, the landscape is shifting toward more diverse, convenient options. Competitive pressure is intensifying as pharmaceutical companies pivot from traditional intravenous corticosteroids toward targeted immunomodulatory agents.

Future growth hinges on a robust pipeline of late-stage candidates designed to address both active and chronic disease states. Notable developments include Viridian’s elegrobart, Roche’s satralizumab, and Sling Therapeutics’ linsitinib, an oral small-molecule candidate. These emerging therapies aim to improve patient outcomes through subcutaneous and oral delivery methods, potentially offering best-in-class safety profiles and reduced treatment burdens. As these candidates progress through clinical trials and regulatory reviews, the standard of care is expected to evolve, favoring personalized, targeted intervention over broad symptomatic management.